The FDA has approved talazoparib for the treatment of metastatic BC patients carrying germline BRCA1/2 mutations, and a meta-analysis has confirmed that PARP inhibitors significantly delay the deterioration in the quality of life (HR, 0.40; 95% CI 0.29–0.54) [10]. The gene discussed is BRCA1; the disease is breast cancer.